Skip to the main content

Meeting abstract

https://doi.org/10.15836/ccar2026.46

Sedation options in a cardiac catheterization laboratory and coronary care unit: protocol review and clinical experience from General Hospital Slavonski Brod

Josip Silović orcid id orcid.org/0009-0002-9918-7575 ; General Hospital “Dr. Josip Benčević”, Slavonski Brod, Croatia
Domagoj Mišković orcid id orcid.org/0000-0003-4600-0498 ; General Hospital “Dr. Josip Benčević”, Slavonski Brod, Croatia
Ivan Majdandžić orcid id orcid.org/0009-0006-0014-6642 ; General Hospital “Dr. Josip Benčević”, Slavonski Brod, Croatia
Marijana Knežević Praveček orcid id orcid.org/0000-0002-8727-7357 ; General Hospital “Dr. Josip Benčević”, Slavonski Brod, Croatia
Katica Cvitkušić Lukenda orcid id orcid.org/0000-0001-6188-0708 ; General Hospital “Dr. Josip Benčević”, Slavonski Brod, Croatia


Full text: english pdf 186 Kb

page 46-47

downloads: 94

cite

Download JATS file


Abstract

Keywords

coronary care unit; sedation; propofol; dexmedetomidine; remifentanil

Hrčak ID:

343432

URI

https://hrcak.srce.hr/343432

Publication date:

15.1.2026.

Visits: 233 *



Introduction: Modern cardiac catheterization laboratories and coronary care units (CCU) require sophisticated sedation protocols that balance patient comfort with hemodynamic stability and respiratory safety (1). This review presents sedation options currently implemented at General Hospital Slavonski Brod’s CCU.

Protocols and Methods: We analyzed seven primary sedation agents used in our institution: propofol and propofol TCI (Target-Controlled Infusion), remifentanil TCI, dexmedetomidine, sufentanil, fentanyl, and midazolam. Each agent’s pharmacokinetics, pharmacodynamics, indications, contraindications, and adverse effects were systematically reviewed based on current literature and institutional experience (Table 1 andTable 2). Our sedation protocols are tailored to specific procedures: propofol for electrical cardioversion due to rapid onset and recovery (2); midazolam combined with propofol for transcatheter aortic valve implantation procedures; dexmedetomidine for mechanically ventilated patients post-cardiac arrest or myocardial infarction; and dexmedetomidine-based protocols for anxious elderly patients and non-invasive ventilation (NIV) mask tolerance enhancement (3,4). Each approach considers patient-specific factors including age, comorbidities, and procedural complexity. Propofol demonstrates rapid onset (30-40 seconds) with significant cardiovascular depression but predictable recovery. TCI systems provide superior concentration control and reduced side effects. Remifentanil TCI offers precise analgesia control with ultra-short elimination half-life (3-10 minutes) but requires vigilant respiratory monitoring. Dexmedetomidine provides unique conscious sedation with minimal respiratory depression, making it ideal for prolonged sedation and NIV tolerance (3,4). Traditional opioids (fentanyl, sufentanil) and midazolam remain valuable for specific indications with established safety profiles. Each agent presents distinct contraindication patterns. Propofol requires caution in cardiac failure and hypovolemia (2). Dexmedetomidine necessitates monitoring for bradycardia and hypotension. Opioids demand respiratory surveillance, while midazolam may cause paradoxical reactions in elderly patients.

TABLE 1 Contraindications and special warnings.
DrugAbsolute contraindicationsRelative contraindicationsSpecial warnings
PropofolAllergy to propofol, eggs, soyHeart failure, hypovolemiaPropofol infusion syndrome, hypertriglyceridemia
Remifentanil TCIAllergy to fentanyl analoguesSevere renal/hepatic insufficiency, COPD, mechanical obstruction of the GITMuscle rigidity, respiratory depression
DexmedetomidineNo absolute contraindicationsBradycardia <50/min, hypotension, heart blockBradycardia, prolonged action in the elderly
Sufentanil/ FentanylAllergy to opioid analgesics, acute asthmaCNS depression, increased intracranial pressureRespiratory depression, addiction
MidazolamAllergy to benzodiazepines, acute glaucomaDementia, COPD, myasthenia gravisDelirium in the elderly, anterograde amnesia
TCI – Target-Controlled Infusion; COPD – Chronic Obstructive Pulmonary Disease; CNS – Central Nervous System; GIT – Gastrointestinal Tract
TABLE 2 Pharmacokinetics and pharmacodynamics.
DrugMechanism of actionOnset of actionElimination half-timeCardiovascular effectsRespiratory effects
PropofolGABA receptor agonist30-40 seconds4-7 hoursHypotension, ↓CO, bradycardiaRespiratory depression, apnea
Propofol TCIGABA receptor agonist30-40 seconds4-7 hoursHypotension, ↓CO, bradycardiaRespiratory depression, apnea
Remifentanil TCIμ-opioid receptor agonist1-3 minutes3-10 minutesBradycardia, hypotensionSignificant respiratory depression
Dexmedetomidineα2-adrenoreceptor agonist15 minutes (without loading dose)2-3 hoursBradycardia, hypotension, initial hypertensionMinimal respiratory depression
Sufentanilμ-opioid receptor agonist1-3 minutes2.5-3 hoursBradycardia, mild hypotensionSignificant respiratory depression
Fentanylμ-opioid receptor agonist1-2 minutes3-4 hoursBradycardia, mild hypotensionModerate respiratory depression
MidazolamGABA-A receptor agonist1-3 minutes1-4 hoursMinimalMild respiratory depression
TCI – Target-Controlled Infusion; ↓CO – Decreased Cardiac Output; GABA – gamma-aminobutyric acid

Conclusions: Successful sedation in cardiac catheterization laboratories and coronary units require individualized approaches based on pharmacological understanding, procedural requirements, and patient characteristics. Our institutional experience demonstrates that combined protocols utilizing multiple agents can optimize patient outcomes while maintaining safety. Continuous monitoring and staff education remain paramount for safe sedation practice.

LITERATURE

1 

Bangalore S, Barsness GW, Dangas GD, Kern MJ, Rao SV, Shore-Lesserson L, et al. Evidence-Based Practices in the Cardiac Catheterization Laboratory: A Scientific Statement From the American Heart Association. Circulation. 2021 August 3;144(5):e107–19. https://doi.org/10.1161/CIR.0000000000000996 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/34187171

2 

Desai PM, Kane D, Sarkar MS. Cardioversion: What to choose? Etomidate or propofol. Ann Card Anaesth. 2015 July-September;18(3):306–11. https://doi.org/10.4103/0971-9784.159798 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/26139733

3 

Akhtar MH, Haleem S, Tauheed N, Khan D. Dexmedetomidine as Conduit for Non-Invasive Ventilation (NIV) Compliance in COVID-19 and Chronic Obstructive Pulmonary Disease (COPD) Patients in Intensive Care Unit (ICU) Setting: Case Series. Cureus. 2023 January 19;15(1):e33981. https://doi.org/10.7759/cureus.33981 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/36811041

4 

Altınkaya Çavuş M, Gökbulut Bektaş GS, Turan S. Comparison of clinical safety and efficacy of dexmedetomidine, remifentanil, and propofol in patients who cannot tolerate non-invasive mechanical ventilation: A prospective, randomized, cohort study. Front Med (Lausanne). 2022;9:995799. https://doi.org/10.3389/fmed.2022.995799 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/36111123


This display is generated from NISO JATS XML with jats-html.xsl. The XSLT engine is libxslt.